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Background: PYY(1-36) peptides from phylogenetically ancient fish, such as sea lamprey, 
have previously been shown to function as specific neuropeptide Y1 receptor (NPYR1) 
agonists. Although, sea lamprey PYY(1-36) is N-terminally stable, we reveal in this study that 
the peptide is subject to endopeptidase mediated C-terminal dipeptide degradation. In an 
attempt to prevent this, (D-Arg35)-sea lamprey PYY(1-36) was developed  
Methods: In vitro bioassays assessed enzymatic stability, insulinostatic activity as well as beta-
studies examined the impact of twice daily administration of sea lamprey PYY(1-36) or (D-
Arg35)-sea lamprey PYY(1-36) in multiple low dose STZ-induced diabetic mice. 
Results: (D-Arg35)-sea lamprey PYY(1-36) was fully resistant to plasma enzymatic 
degradation. The peptide possessed similar significant NPYR1-mediated insulinostatic, as well 
as positive beta-cell proliferative and anti-apoptotic biological actions, as the parent peptide. 
Sea lamprey PYY(1-36) and (D-Arg35)-sea lamprey PYY(1-36) delayed diabetes progression 
in STZ mice. Both treatment interventions induced a significant decrease in body weight, food 
and fluid intake as well as glucose and glucagon concentrations. In addition, glucose tolerance, 
plasma and pancreatic insulin were partially normalised. (D-Arg35)-sea lamprey PYY(1-36) 
was significantly more effective than sea lamprey PYY(1-36) in terms of enhancing glucose-
stimulate insulin release. Both treatments improved pancreatic islet morphology, linked to 
augmented proliferation and decreased apoptosis of beta-cells.  
Conclusion: We present (D-Arg35)-sea lamprey PYY(1-36) as the first-in-class N- and C-
terminally stable PYY(1-36) peptide analogue. 
General significance: Enzymatically stable, long-acting PYY(1-36) peptides highlight the 
therapeutic benefits of sustained activation of NPYR1’s in diabetes. 
 
1. Introduction  
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The beneficial effects of sustained modulation of pancreatic beta-cell neuropeptide Y1 
receptors (NPY1R’s) by the 36 amino acid gut-derived peptide hormone, Peptide Tyrosine 
Tyrosine (PYY), are now acknowledged [1,2]. As such, acute activation of beta-cell NPY1R’s 
was initially shown to encourage inhibition of glucose-stimulated insulin secretion (GSIS) and 
produce beta-cell rest [3]. However, later studies revealed positive effects of more prolonged 
PYY(1-36)-induced NPY1R activation on growth, survival and overall secretory function of 
pancreatic beta-cells [1,2,4,5], with obvious related benefits for the treatment of diabetes [1]. 
However, the therapeutic efficacy of native PYY(1-36) is significantly hampered by rapid 
enzymatic degradation and loss of NPY1R specificity. In this regard, the ubiquitous enzyme 
dipeptidyl peptidase-4 (DPP-4) removes the N-terminal Tyr1-Ala2 dipeptide from PYY(1-36) 
to yield PYY(3-36) [6], a degradation fragment with postulated anti-obesity actions [7]. 
However, this DPP-4 mediated enzymatic reaction dramatically reduces the affinity of PYY 
for NPY1R’s [8], severely diminishing therapeutic applicability for diabetes.  
 To circumvent this issue, a number of PYY(1-36) peptide analogues with N-terminally 
stability and postulated NPYR1 specificity have recently been described [2,9]. At first, 
utilisation of available structure/function knowledge in the field of PYY/NPYR1 led to the 
generation of PYY(1-36) molecules with logically introduced  amino acid substitutions or 
secondary modifications, namely (P3L31P34)PYY(1-36) and PYY(1-36)(Lys12PAL), 
respectively [9]. However, the biological effectiveness of these synthetic PYY(1-36) analogues 
was markedly reduced when compared to the parent peptide [9], dismissing antidiabetic utility. 
Following on from this, PYY(1-36) peptide sequences from phylogenetically ancient fish, with 
intrinsic DPP-4 resistance, were also investigated as potential specific NPYR1 modulators [2]. 
As such, Amia calva (bowfin), Oncorhynchus mykiss (trout), Petromyzon marinus (sea 
lamprey) and Scaphirhynchus albus (sturgeon) effectively activated rodent and human 
pancreatic beta-cell NPYR1’s, and possessed a pharmacodynamic profile superior to native 
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PYY(1-36) [2]. Sea lamprey PYY(1-36) proved to be the most efficacious fish-derived 
compound and induced notable improvements on pancreatic islet morphology and insulin 
secretion following sustained treatment in multiple low dose streptozotocin (STZ)-induced 
diabetic mice [2].  
Despite the clear antidiabetic benefits of N-terminally stabilised sea lamprey PYY(1-
36), the importance of C-terminal stability for preserved bioactivity of PYY-based peptides has 
been documented of late [10,11]. Thus, C-terminal dipeptide cleavage of PYY(3-36), to yield 
PYY(3-34), occurs naturally within the circulation and annuls the well-described anorexic 
effects of this PYY fragment-peptide [10]. For PYY(1-36) a similar C-terminal degradation 
process occurs, rendering the peptide inactive at the level of the pancreatic beta-cell [11]. 
Notably, the C-terminal region of sea lamprey PYY(1-36) exhibits distinct amino acid 
sequence homology with native human PYY(1-36) [2]. Therefore, in the present study we 
initially demonstrated degradation of sea lamprey PYY(1-36) to (1-34) in plasma. Further 
studies examined the impact of substitution of L-Arg35 with its enantiomer D-Arg35 in sea 
lamprey PYY(1-36), to yield (D-Arg35)-sea lamprey PYY(1-36), on metabolic stability as well 
as in vitro pancreatic beta-cell function, growth and survival, alongside NPYR specificity. 
Essentially, (D-Arg35)-sea lamprey PYY(1-36) represents the parent sea lamprey PYY(1-36) 
peptide, where the L-Arg amino acid residue at position 35 is replaced with its own mirror 
image, known as D-Arg35. In addition, the impact twice daily treatment with (D-Arg35)-sea 
lamprey PYY(1-36), or the parent peptide, on metabolic control and pancreatic architecture 
was investigated in multiple low dose streptozotocin (STZ)-induced diabetic mice.  
 
2. Methods  
2.1 Peptides  
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All peptides (Table 1) were supplied by Synpeptide Ltd (Shanghai, China) at greater than 95% 
purity and characterised in-house by HPLC with MALDI-TOF, as described previously [12].  
 
2.2 Plasma degradation  
Sea lamprey and (D-Arg35)-sea lamprey PYY(1-36) peptides (50 µg) were incubated at 37oC 
on a plate-shaker in 50 mM triethanolamine/HCl (pH 7.8) with 5 µl of fasted murine plasma 
for 0 and 8 hours. Reactions were terminated by addition of 10 µl of 10% (v/v) trifluoroacetic 
acid/water. Reaction mixes were separated on RP-HPLC using a (250 x 4.6 mm) Phenomenex 
C-18 analytical column, with absorbance monitored at 214 nm using a Thermoquest, 
SpectraSystem UV2000 detector. Defined HPLC peaks were collected and identified via 
MALDI-TOF MS on a PerSeptive Biosystems Voyager-DE Biospectrometer (Hertfordshire, 
UK).  
 
2.3 In vitro insulin secretion  
In vitro effects of PYY(1-36) peptides on insulin secretion were determined using rodent BRIN 
BD11 beta-cells. The characteristics of this cell line, including glucose-sensitivity and insulin 
secretory function, have been described in detail elsewhere [13]. Importantly, BRIN BD11 
cells have been shown to abundantly express the NPYR1 [4], and have been successfully 
utilised for assessment of beta-cell actions of various PYY peptides [1,2,9,11]. Cells were 
cultured in RPMI 1640 media (Gibco Life Technologies Ltd), supplemented with 10% v/v 
foetal bovine serum (Gibco), 1% v/v antibiotics (0.1 mg/ml streptomycin and 100 U/ml 
penicillin) at 37oC in 5% atmospheric CO2. For experimentation, cells were seeded into 24-
well plates (Falcon Ltd) at a density of 150,000 cells per well. Following overnight attachment, 
media was aspirated and cells were pre-incubated in 1.1 mM glucose KRB buffer for 40 
minutes. Following pre-incubation, the 1.1 mM glucose solution was removed and 1 ml of 
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KRB test solution, containing either 5.6 or 16.7 mM glucose with either sea lamprey PYY(1-
36) or (D-Arg35)-sea lamprey PYY(1-36) (10-12 – 10-6 M) was added. We have routinely shown 
that 5.6 mM glucose has insulin secretory stimulatory effects in BRIN-BD11 cells above basal 
output, which is further augmented at 16.7 mM glucose [11,14-16]. In a second series of 
experiments, insulin secretory effects of PYY(1-36) peptides were determined following 
incubation in the presence of alanine (10 mM) at 16.7 mM glucose. For all experiments, 
following a 20 min incubation period, supernatant was collected and stored at -20oC until 
required for insulin concentration determination using a dextran coated charcoal insulin 
radioimmunoassay [17].  
 
2.4 Beta-cell proliferation and apoptosis  
To assess the effects (10-8 and 10-6 M) of sea lamprey PYY(1-36) and (D-Arg35)-sea lamprey 
PYY(1-36) on beta-cell proliferation and protection against apoptosis, rodent BRIN-BD11 and 
human 1.1B4 beta-cells [18] were used. Functional characteristics and suitability of 1.1B4 cells 
as a proxy for primary human beta-cells in studies of insulin secretion, beta-cell growth and 
protection are provided by the original publication and subsequent papers that have been 
reviewed [15,19]. 1.1B4 cells used in the present studies were well differentiated as confirmed 
by routine measurements of cellular insulin content and responsiveness to a range of 
secretagogues, which were in line with these earlier studies. Cells were seeded onto sterilised, 
clear-glass coverslips (16 mm diameter) and placed in 12-well plates (Falcon Ltd) at a density 
of 40,000 cells per well and cultured for 18 h. Media control, GLP-1 (10-8 and 10-6 M) and a 
human cytokine cocktail mix (IL-1β (100 U/mL), IFNγ (20 U/mL), TNFα (200 U/mL), Sigma 
Aldrich UK) were employed as controls, as appropriate. Cells were then rinsed with PBS and 
fixed using 4% paraformaldehyde. After antigen retrieval with sodium citrate buffer at 95oC 
for 20 min, blocking was performed using 2% BSA for 45 min. To assess the ability of PYY(1-
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36) peptides to protect against cytokine-induced apoptosis, BRIN BD11 and 1.1B4 cells were 
seeded, washed and fixed as above, with the exception that the media was supplemented with 
the cytokine mix. The coverslips were then incubated at 37oC with TUNEL reaction mix 
(Roche Diagnostics Ltd, UK) for 60 min, and mounted onto polysine-coated microscope slides 
using a 50:50 Glycerol:PBS solution and stored at 4oC until required for analysis. For 
proliferation studies, the coverslips were incubated at 37oC with rabbit anti-Ki-67 primary 
antibody (Abcam, ab15580), and subsequently with Alexa Fluor® 488 secondary antibody 
(Invitrogen, UK), and mounted onto microscope slides as above. In a separate study, beta-cell 
proliferative effects were examined in INS1 832/13 cells with CRISPR-Cas9 induced knockout 
(KO) of either the Npy1r or Npyr2, with generation and characterisation of both KO cell lines 
described in detail elsewhere [2]. INS1 832/13 cells were selected for KO studies because of 
their better transfection efficiency when compared to BRIN BD11 cells [2]. All slides were 
viewed using a fluorescent microscope (Olympus System Microscope, model BX51; 
Southend-on-Sea, UK) and photographed by DP70 camera adapter system. 
Proliferation/TUNEL positive frequency was determined using the cell-counter function on 
ImageJ Software and expressed as a percentage of total cells in proliferation experiments or as 
a fold-change of the cytokine cocktail control in apoptosis experiments. 
 
2.5 Sub-chronic in vivo effects  
NIH male Swiss TO mice (14 weeks of age, Envigo Ltd, UK) received twice-daily treatment 
with either saline vehicle, sea lamprey PYY(1-36) or (D-Arg35)-sea lamprey PYY(1-36)  (both 
at 25  nmol/kg bw; n=10) for the first three days of the experiment. On day 3, mice received 
multiple low dose streptozotocin (STZ) injection (4 h fast, 50 mg/kg bw, i.p., in sodium citrate 
buffer, pH 4.5) for 5 consecutive days to induce diabetes. Twice-daily treatment interventions 
continued during this diabetes induction phase and up until day 14. An additional group of 
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control mice (n=10) were maintained on normal laboratory chow throughout (10% fat, 30% 
protein and 60% carbohydrate, Trouw Nutrition, UK), were injected twice-daily with saline 
rather than STZ. Cumulative energy and fluid intake, body weight, circulating glucose and 
insulin concentrations were assessed at regular intervals, with plasma glucagon measured on 
day 14. At the end of the treatment period, glucose tolerance and glucose-induced insulin 
secretion in response to an i.p. glucose load (18 mmol/kg bw) was assessed. All animal 
experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 
1986 and EU Directive 2010/63EU for animal experiments. The study was approved by Ulster 
University Animal Welfare Ethical Review Body (AWERB). Terminal analyses included 
extraction of pancreatic tissue and appropriate processing for measurement of hormone content 
following acid/ethanol protein extraction or islet architecture, as described previously [2]. This 
included co-staining for insulin (1:500; Abcam, ab6995) or glucagon (PCA2/4, 1:200; raised 
in-house) with either Ki-67 (1:400; Abcam ab15580) to assess proliferation rate or TUNEL 
reaction mixture (Roche Diagnostics Ltd, UK) to quantify cell apoptosis. As such, following 
incubation with primary antibodies, appropriate secondary antibodies were employed, namely 
Alexa Fluor® 594 goat anti-mouse IgG (1:400), Alexa Fluor® 488 goat anti-guinea pig IgG 
(1:400) and Alexa Fluor® 488 goat anti-rabbit IgG as appropriate. Slides were viewed under a 
FITC (488 nm) or TRITC filter (594 nm) using a fluorescent microscope (Olympus system 
microscope, model BX51) and photographed using a DP70 camera adapter system. Islet 
parameters were analysed using CellF image analysis software (Olympus Soft Imaging 
Solutions, GmbH).   
 
2.6 Biochemical analyses 
Blood samples were collected from the cut tip on the tail vein, of conscious mice, at times 
indicated in Figures. Blood glucose was measured immediately using a hand-held Ascencia 
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Contour blood glucose meter (Bayer Healthcare, Newbury, Berkshire, UK). For plasma insulin 
and glucagon, blood was collected in chilled fluoride/heparin coated micro-centrifuge tubes 
(Sarstedt, Numbrecht, Germany) and centrifuged using a Beckman micro-centrifuge (Beckman 
Instruments, Galway, Ireland) for 10 minutes at 12,000 rpm. Plasma was separated and stored 
at -20oC, until determination of plasma insulin by radioimmunoassay [17] or glucagon by a 
commercially available ELISA kits (EZGLU-30K, Merck Millipore).  
2.7 Statistical analysis  
Statistical analyses were performed using GraphPad PRISM software (Version 5.0). Values are 
expressed as mean ± S.E.M. Comparative analyses between groups were carried out using a 
One-way ANOVA with Bonferroni’s post hoc test or student's unpaired t-test, as appropriate. 
The difference between groups was considered significant if p < 0.05. 
 
3. Results  
3.1 In vitro murine plasma stability  
Incubation of human PYY(1-36) with murine plasma for 8 h resulted in generation of the N- 
and C-terminally truncated products PYY(3-36) and PYY(1-34) (Fig. 1A). In the same 
experimental system, the only observable degradation product of sea lamprey PYY(1-36) was 
sea lamprey PYY(1-34) (Fig. 1B). However, (D-Arg35)-sea lamprey PYY(1-36) was 
completely resistant to enzymatic degradation over the 8 h period with no evident degradation 
peaks (Fig. 1C).  
 
3.2 Effects of PYY(1-36) peptides on insulin secretion from BRIN BD11 beta-cells  
All PYY peptides, namely human PYY(1-36), sea lamprey PYY(1-36) and (D-Arg35)-sea 
lamprey PYY(1-36), significantly (p < 0.05 to p < 0.001) inhibited insulin secretion from BRIN 
BD11 cells at both 5.6 and 16.7 mM glucose concentrations (Fig. 2A,B). Notably, there was 
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an approximate 30% increase in insulin secretory output at 16.7 mM glucose, when compared 
to 5.6 mM glucose (Fig. 2A,B). At 5.6 mM glucose, sea lamprey PYY(1-36) was more effective 
(p < 0.05 to p < 0.001) that human PYY(1-36) at concentrations of 10-8 M and above (Fig. 2A). 
In addition, all PYY(1-36) peptides (10-7 and 10-6 M) inhibited (p < 0.01 to p < 0.001) alanine-
induced elevations of insulin release (Fig. 2C). However, only human PYY(1-36) and sea 
lamprey PYY(1-36) exerted inhibitory (p < 0.05 to p < 0.001) effects at concentrations below 
10-7 M (Fig. 2C).  
 
3.3 Effects of PYY(1-36) peptides on beta-cell proliferation and protection against cytokine-
induced apoptosis  
All PYY(1-36) peptides (10-8 and 10-6 M) significantly (p < 0.05 to p < 0.001) augmented BRIN 
BD11 and 1.1B4 beta-cell proliferation, to a similar, or greater, extent as observed with the 
positive control GLP-1 (Fig. 3A,B). Notably, (D-Arg35)-sea lamprey PYY(1-36) was 
significantly (p < 0.05) more effective than native PYY(1-36) at 10-6 M in 1.1B4 cells (Fig. 
3B). In order to determine receptor interactions involved in these beta-cell proliferative actions, 
Npy1r and Npyr2 KO INS1 832/13 cells were employed (Fig. 3C). As expected, all peptides 
(at either 10-6 or 10-8 M) effectively (p < 0.05 to p < 0.01) promoted beta-cell proliferation in 
INS1 832/13 wild-type cells (Fig. 3C). However, all PYY(1-36) peptides were ineffective in 
terms of stimulating proliferation in Npy1r KO INS1 832/13 cells, but did induce (p < 0.05 to 
p < 0.01) beta-cell growth in Npy2r KO cells (Fig. 3C). All test peptides, including GLP-1 
positive control, imparted similar significant (p < 0.05 to p < 0.001) protective effects against 
cytokine-induced apoptosis in both BRIN BD11 (Fig. 3D) and 1.1 B4 (Fig. 3E) beta-cells.  
 
3.4 Sub-chronic effects of PYY(1-36) peptides on various metabolic parameters as well as 
pancreatic hormone content in STZ-induced diabetic mice  
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Initiation of STZ injection on day 3 resulted in progressive (p < 0.05 to p < 0.01) weight loss 
during the observation period in saline treated mice, with this weight reducing effect annulled 
by twice daily sea lamprey PYY(1-36) or (D-Arg35)-sea lamprey PYY(1-36) injection (Fig. 
4A). Accumulated food and fluid intake were elevated (p < 0.05 to p < 0.01) in STZ-diabetic 
mice on days 12 and 14 (Fig. 4B,C). Sea lamprey PYY(1-36) and (D-Arg35)-sea lamprey 
PYY(1-36) treatment significantly (p < 0.05 to p < 0.01) suppressed STZ-induced effects on 
food and fluid intake (Fig. 4B,C), with food intake in these mice being similar to lean controls 
(Fig. 4B). Circulating blood glucose was substantially elevated (p < 0.001) in STZ-diabetic 
mice from day 8 onwards when compared to lean controls (Fig. 4D). This rise in blood glucose 
was significantly (p < 0.05 to p < 0.01) reduced by both PYY(1-36) treatment regimens, and 
indeed non-fasting glucose levels in these mice were not significantly different from lean 
controls on day 14 (Fig. 4D). Corresponding insulin concentrations were dramatically 
decreased (p < 0.001) in saline treated STZ-diabetic mice (Fig. 4E). Both sea lamprey PYY(1-
36) and (D-Arg35)-sea lamprey PYY(1-36) slowed the progression of decreases in insulin 
concentrations (Fig. 4E). In terms of plasma glucagon concentrations, STZ-induced diabetes 
significantly (p < 0.001) elevated this parameter on day 14, with both sea lamprey PYY(1-36) 
and (D-Arg35)-sea lamprey PYY(1-36) fully reversing the effect (Fig. 4F). Indeed, twice-daily 
treatment with sea lamprey PYY(1-36) significantly (p < 0.05) reduced circulating glucagon 
when compared to STZ-diabetic controls (Fig. 4F).  
During glucose tolerance tests at the end of the treatment period, plasma glucose levels 
were significantly (p < 0.01 to p < 0.01) elevated in STZ-diabetic mice when compared to lean 
controls (Fig. 4G). Sea lamprey PYY(1-36) treatment reduced glucose levels at 15, 30, 60 and 
90 min post‐injection (Fig. 4G), with (D-Arg35)-sea lamprey PYY(1-36) inducing a significant 
(p < 0.05) reduction at 30 mins post-injection (Fig. 4G). Related AUC analysis confirmed an 
elevated (p < 0.01) glycaemic excursion in saline treated STZ-diabetic mice, which was not 
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apparent in either of the PYY(1-36) peptide treated groups (Fig. 4I). As expected, the 
corresponding glucose-induced insulin secretory response in STZ-diabetic control mice 
animals was significantly (p < 0.05 to p < 0.001) reduced in terms of individual and overall 
values when compared to lean control mice (Fig. 4H,J). Both sea lamprey PYY(1-36) and (D-
Arg35)-sea lamprey PYY(1-36) also had a reduced (p < 0.05 to p < 0.001) plasma insulin 
secretory response when compared to lean mice, but overall AUC values were significantly (p 
< 0.01) greater in (D-Arg35)-sea lamprey PYY(1-36) mice when compared to diabetic controls 
(Fig. 4H,J). Assessment of both pancreatic insulin and glucagon content on day 14 revealed 
dramatically (p < 0.001) decreased insulin and increased glucagon concentrations in STZ-
diabetic mice (Fig. 4K,L). Both PYY(1-36) treatments almost fully reversed these detrimental 
effects (Fig. 4K,L), however sea lamprey PYY(1-36) treated mice still presented with slightly 
(p < 0.05) decreased pancreatic insulin concentrations compared to lean controls (Fig. 4K). 
 
3.5 Sub-chronic effects of PYY(1-36) peptides on pancreatic morphology in STZ-induced 
diabetic mice  
Histological analysis of pancreatic tissue highlighted the negative morphological consequences 
STZ injection, which appeared to be countered by twice-daily sea lamprey PYY(1-36) and (D-
Arg35)-sea lamprey PYY(1-36) treatment (Fig. 5A-D). Indeed, quantification of pancreatic islet 
area revealed substantially (p < 0.001) smaller islets in STZ-diabetic mice, which were 
significantly (p < 0.001) enlarged in all PYY(1-36) peptide treated mice (Fig. 5E). In keeping 
with this, percentage beta-cell area was significantly (p < 0.001) lower in all STZ mice, but 
increased (p < 0.001 and p < 0.01; respectively) by sea lamprey PYY(1-36) and (D-Arg35)-sea 
lamprey PYY(1-36) treatment (Fig. 5F). In addition, percentage α-cell area was elevated (p < 
0.001) in all STZ mice, but reduced by both treatment interventions (Fig. 5G). However, it 
should also be noted that these islet, beta- and alpha-cell parameters were still significantly 
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different from lean controls in all PYY(1-36) peptide treated mice (Fig. 5E-G). Despite this, 
alpha:beta cell ratios were similar in both sea lamprey PYY(1-36) and (D-Arg35)-sea lamprey 
PYY(1-36) treated STZ mice as compared to lean controls, and significantly (p < 0.001) 
reduced when compared to STZ-diabetic controls (Fig. 5H). Furthermore, islets of saline 
treated STZ-diabetic mice had significantly (p < 0.001) more centrally-located α-cells, a 
phenomenon which was reversed by both PYY(1-36) peptide treatments (Fig. 5I). In addition, 
both sea lamprey PYY(1-36) and (D-Arg35)-sea lamprey PYY(1-36) returned islet numbers to 
lean control levels (Fig. 5J). To uncover the mechanisms behind islet morphological changes, 
alpha- and beta-cell proliferation and apoptosis frequency was examined (Fig. 6). STZ-diabetic 
mice exhibited significantly (p < 0.001) decreased beta-cell proliferation and increased beta-
cell apoptosis (Fig. 6A,C). Both treatment interventions significantly (p < 0.001) increased 
beta-cell proliferation and returned beta-cell apoptosis rates to lean control levels (Fig. 6A,C). 
There was no change in alpha-cell proliferation in any of the groups of mice (Fig. 6B), but 
alpha-cell apoptosis was significantly (p < 0.001) elevated in STZ controls (Fig. 6D). Effects 
on alpha-cell apoptosis were fully or partially reversed by (D-Arg35)-sea lamprey PYY(1-36) 
and sea lamprey PYY(1-36), respectively (Fig. 6D).  
 
4. Discussion  
Recent studies with sea lamprey PYY(1-36) confirm that this peptide, derived from a 
phylogenetically-ancient fish, represents an N-terminally stabilised mammalian NPYR1 
activator, with notable beneficial beta-cell effects following chronic administration in STZ-
treated mice with established insulin deficiency and diabetes [2]. However, in the present study 
we reveal, for the first time, that sea lamprey PYY(1-36) is susceptible to C-terminal dipeptide 
degradation. This is of particular importance given that C-terminal truncation of PYY(1-36) 
dramatically impairs NPYR1 activation profile of the peptide [11]. 
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 To circumvent C-terminal degradation of sea lamprey PYY(1-36), (D-Arg35)-sea 
lamprey PYY(1-36) was generated and characterised. In this regard, it is suggested that the 
Arg35 residue is the target for the, as yet unidentified, C-terminally directed endopeptidase that 
degrades PYY peptides [10,20]. Thus, although the angiotensin-converting-enzyme (ACE) 
inhibitor, captopril, blocks C-terminal dipeptide cleavage of PYY peptides [11], there is no 
direct evidence for ACE-mediated truncation of PYY(1-36) [21]. Moreover, co-incubation of 
PYY(1-36) with captopril in plasma still leads to generation of the C-terminally truncated 
product PYY(1-35), which also lacks ability to modulate NPYR1 function [11]. Nevertheless, 
substitution of naturally occurring L- for D-isomers in specific amino acid residues targeted by 
enzymes within peptide hormones has been demonstrated as a relatively straightforward 
strategy to induce enzyme resistance, with minimal detrimental impact on receptor binding and 
overall bioactivity [22-25]. In full agreement, (D-Arg35)-sea lamprey PYY(1-36) was 
completely stable against plasma enzyme mediated degradation and possessed a comparable in 
vitro biological action profile as the parent peptide. As such, (D-Arg35)-sea lamprey PYY(1-
36) had clear insulinostatic actions in BRIN BD11 cells, and also promoted beta-cell growth 
and protection against apoptosis [2], which were dependent on NPYR1 activation. 
 Based on these observations, the ability of (D-Arg35)-sea lamprey PYY(1-36), or the 
parent peptide, to protect against STZ-induced insulin deficiency was examined. As observed 
previously with sustained NPYR1 activation [2], twice-daily treatment of mice with either of 
the PYY(1-36) peptides, partially or fully, protected from the characteristic weight loss, 
increased fluid and food intake, as well as elevated blood glucose levels, evoked by repeated 
low-dose STZ administration. In keeping with this, pancreatic and plasma glucagon levels were 
noticeably decreased by both treatments, this being despite knowledge that PYY peptides do 
not directly modulate glucagon secretion [26], indicating indirect effects on alpha-cell function. 
Interestingly, pancreatic insulin content was markedly elevated by both interventions, and this 
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translated to protection from a decline in circulating insulin. In addition, there was a significant 
improvement of beta-cell secretory function in (D-Arg35)-sea lamprey PYY(1-36) treated mice, 
as evidenced following exogenous glucose injection at the end of the treatment period. In 
agreement, augmented NPYR1 activation has been linked to the well-established beta-cell 
secretory benefits following Roux-en Y gastric bypass (RYGB) surgery in humans [5]. 
Moreover, circulating levels of PYY(1-36) are diminished in type 2 diabetic patients, who are 
recognised to present with impaired beta-cell secretory function [27]. In addition, metabolic 
improvements induced by (D-Arg35)-sea lamprey PYY(1-36) can also be linked, in part, to in 
vitro observations highlighting clear NPY1R-mediated insulinostatic actions. As such, the 
antidiabetic benefits of beta-cell rest has previously been demonstrated, including reduced 
beta-cell oxidative stress [28], restoration of cellular insulin stores [29] and a reduction of islet 
fibrosis [30]. 
Consistent with pancreatic islet benefits following (D-Arg35)-sea lamprey PYY(1-36) 
treatment, beta-cell proliferation was enhanced and apoptosis decreased in these mice, fully 
consistent with in vitro observations, albeit sea lamprey PYY(1-36) evoked essentially similar 
positive effects. Thus, the previously documented pancreatic morphological benefits of 
sustained administration of sea lamprey PYY(1-36) in established STZ-diabetic mice [2], were 
largely recapitulated during development and establishment of diabetes in the current study by 
both PYY(1-36) peptide treatments. Related mechanisms are most likely connected to NPYR1 
downstream signalling and increased cellular PKC epsilon activity [31], which couples via 
mitochondrial pathways to inhibit cell apoptosis [32]. Furthermore, PYY has been shown to 
protect beta-cells against cytokine-induced apoptosis via inhibition of nuclear factor κB (NF-
κB) [33]. Notable pancreatic benefits in the current study included increased islet numbers and 
beta-cell area, reduced alpha-cell area and glucagon positively stained central islet cells, as well 
as improved alpha:beta cell ratios. Notably, increased centralised pancreatic alpha-cells 
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represents a unique indicator of islet disturbance in rodents [34]. Such observations also 
correlate closely with knowledge that selective knockout of PYY expressing cells diminishes 
beta-cell area and moderates secretory function of these cells [35]. Furthermore, apoptotic rate 
of pancreatic alpha-cells was decreased by both sea lamprey PYY(1-36) treatment regimens, 
yet proliferation remained unchanged, with this effect being much more pronounced in (D-
Arg35)-sea lamprey PYY(1-36) treated mice. This observation, coupled with the related impact 
on alpha-cell area and pancreatic glucagon content, could imply positive effects of sea lamprey 
PYY(1-36) peptides on pancreatic islet cell plasticity and lineage reprograming [36], but 
confirmation of this requires further detailed study.  
 Although, as noted above, some marginal benefits of (D-Arg35)-sea lamprey PYY(1-
36) over the parent peptide were evident, it is somewhat surprising that C-terminal enzymatic 
stability did not result in more discernible improvements in STZ-diabetic mice, especially since 
in vitro bioactive profiles of the peptides are relatively similar. It is recognised that the C-
terminus of the NPY family of peptides is fundamentally important for receptor binding [37]. 
In this respect, while Arg35 has been noted to be integral for NPYR2 activation, less importance 
is associated with NPYR1 binding [37], supporting our use of the Arg35 enantiomer to evoke 
enzyme resistance in sea lamprey PYY(1-36). However, earlier studies do suggest that the 
guanidine moiety of Arg35 may be involved in NPYR1 binding to some extent [38]. Thus, 
although exchanging the L- for the D-isomer of Arg35 in sea lamprey PYY(1-36) affords full C-
terminal stability, there is a small possibility that this could impede efficient NPYR1 binding 
and downstream signalling, and further study would be required to confirm this. In addition, 
any impact of the D-Arg35 change on the characteristic ‘PP-fold’ conformation of PYY 
peptides, responsible for peptide recognition by the NPYR1 [39], would also need to be 
investigated. However, lack of clear distinction between the antidiabetic efficacy of the two 
sea lamprey PYY(1-36) treatment options could also simply be a consequence of the dose 
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chosen, and severity of the diabetes induced, by repeated low-dose STZ administration, and 
the need to activate complementary signalling pathways to adequately curtail the development 
of overt diabetes. Examination of the pharmacokinetic profile of both PYY(1-36) peptides 
would also be useful in this regard, but beyond the scope of the current study. 
 In conclusion, the present study has generated (D-Arg35)-sea lamprey PYY(1-36) as a 
novel NPY1R agonist with dual N- and C-terminal enzymatic stability. Benefits of (D-Arg35)-
sea lamprey PYY(1-36) to prevent progression of STZ-induced insulin deficiency and diabetes 
were broadly similar to the parent peptide, sea lamprey PYY(1-36). Previous studies have 
highlighted the difficulty of generating bioactive C-terminally modified PYY peptides [40], 
due to involvement of the C-terminus of the peptide in receptor binding and activation [10,11]. 
However, renal clearance of (D-Arg35)-sea lamprey PYY(1-36) is unlikely to be altered by the 
C-terminal modification, and could be an important factor in terms of overall pharmacological 
efficacy. Thus, secondary modifications to extend the circulating half-life of (D-Arg35)-sea 
lamprey PYY(1-36), such as fatty acid derivation or PEGylation, as successfully employed for 
other related gut-derived hormones [41-44], may be required for realisation of the full 
antidiabetic potential of this treatment approach and future translational benefits.  
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Amino acids in bold text are conserved in human PYY(1-36). Peptide masses were calculated using MALDI-TOF MS on a PerSeptive Biosystems 
Voyager-DE Biospectrometer. Peptide purity was assessed by HPLC and analysis of AUC data. For plasma degradation, peptides (50 µg) were 
incubated at 37oC in 50 mM triethanolamine/HCl with murine plasma (5 µL) for 0 and 8 hours. Defined HPLC peaks were collected and identified 
via MALDI-TOF MS on a PerSeptive Biosystems Voyager-DE Biospectrometer.









degradation at 8 
h 
Human 
PYY(1-36)     Y-P-I-K-P-E-A-P-G-E-D-A-S-P-E-E-L-N-R-Y-Y-A-S-L-R-H-Y-L-N-L-V-T-R-Q-R-Y- NH2 4309.8 4309.7 96.8 83.8 
Sea Lamprey 




     M-P-P-K-P-D-N-P-S-P-D-A-S-P-E-E-L-S-K-Y-M-L-A-V-R-N-Y-I-N-L-I-T-R-Q-(DR)-Y- NH2 4285.9 4283.5 97.8 0 
22 
 
Figure legends  
Fig. 1. HPLC profiles obtained following incubation of (A) PYY(1-36), (B) sea lamprey 
PYY(1-36) and (C) (D-Arg35)-sea lamprey PYY(1-36) with non-fasted murine plasma. 
Peptides (50 µg; n=3) were incubated at 37oC with 5 µl plasma in 50 mM triethanolamine-
HCL. Reactions were stopped using 10% (v/v) trifluoroacetic acid/water and reaction mixes 
separated by HPLC. Peptide or peptide fragment masses were determined by MALDI-TOF.  
 
Fig. 2. Effects of sea lamprey PYY(1-36) peptides on insulin release from rodent BRIN-BD11 
beta-cells. Incubations were performed at (A) 5.6, (B) 16.7 mM glucose or (C) 16.7 mM 
glucose supplemented with alanine (10 mM) and the effects of PYY(1-36) peptides (10-6 – 10-
12 M) on insulin secretion determined. Values are mean ± SEM (n=8). *p < 0.05, **p < 0.01, 
***p < 0.001 compared to (A,B) respective glucose control or (C) 16.7 mM glucose plus 10 
mM alanine. Δp < 0.05, ΔΔp < 0.01, ΔΔΔp < 0.001 compared to (A) human PYY(1-36) or (C) 
16.7 mM glucose. 
 
Fig. 3. Effects of sea lamprey PYY(1-36) peptides on (A-C) beta-cell proliferation and (D,E) 
protection against cytokine-induced apoptosis. (A) BRIN-BD11, (B) 1.1B4 and (C) INS1 
832/13, as well as Npy1r or Npy2r KO INS1 832/13, beta-cells were cultured (16 h) with GLP-
1 or PYY(1-36) peptides (10-8 and 10-6 M) and proliferation assessed by Ki-67 staining. (D) 
BRIN-BD11 and (E) 1.1 B4 beta-cells were cultured (16 h) with GLP-1 or PYY(1-36) peptides 
(10-8 and 10-6 M) in the presence of a cytokine cocktail and apoptosis detected using the 
TUNEL assay. All values are mean ± SEM (n=3). (A-C) *p < 0.05, **p < 0.01, ***p < 0.001 
compared to respective media control. (B) ΔΔp < 0.01 compared to PYY(1-36) (C) Δp < 0.05, 
ΔΔΔp < 0.001 compared to INS1 832/13 wild-type cells at each condition. (D,E) *p < 0.05, **p 
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< 0.01, ***p < 0.001 compared to cytokine-cocktail. Δp < 0.05, ΔΔp < 0.01 compared to RPMI 
media control.  
 
Fig. 4. Effects of sea lamprey PYY(1-36) and (D-Arg35)-sea lamprey PYY(1-36) on various 
metabolic parameters as well as pancreatic insulin and glucagon content in STZ-induced 
diabetic mice. (A-E) Parameters were measured at regular intervals for 3 days before and 14 
days during treatment with twice-daily injection of sea lamprey PYY(1-36) and (D-Arg35)-sea 
lamprey PYY(1-36) (both peptides at 25 nmol/kg bw). As indicated in panels A, D and E, STZ 
administration was initiated on day 3. (F-J) Parameters were measured on day 21. (F) Plasma 
glucagon was measured using a commercially available ELISA kit. (G,I) Blood glucose and 
(H,J) plasma insulin were measured prior to and after i.p. administration of glucose alone 
(18 mmol/kg) at t = 0 min. (K,L) Pancreatic insulin and glucagon content was measured by RIA 
or ELISA, respectively, following acid-ethanol extraction. All values are expressed as 
mean ± SEM for 10 mice. *p < 0.05, **p < 0.01, ***p < 0.001 compared with STZ diabetic 
control mice. Δp < 0.05, ΔΔp < 0.01 and ΔΔΔp < 0.001 compared with lean control mice.  
 
Fig. 5. Effects of sea lamprey PYY(1-36) and (D-Arg35)-sea lamprey PYY(1-36) on pancreatic 
morphology in STZ-induced diabetic mice. All parameters were measured at after 14 days 
treatment with twice-daily injection of sea lamprey PYY(1-36) or (D-Arg35)-sea lamprey 
PYY(1-36) (both at 25 nmol/kg bw). (A-D) Representative images of islets showing insulin 
(red) and glucagon (green) immunoreactivity from each treatment group. (E) Total islet area, 
percentage (F) beta- and (G) alpha-cell area, (H) alpha/beta cell ratio, (I) percentage centrally 
located alpha-cells as well as (J) numbers of islets/mm2. All values are expressed as 
mean ± SEM for 10 mice, with 100-150 islets being analysed per group. *p < 0.05, **p < 0.01, 
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***p < 0.001 compared with STZ diabetic control mice. Δp < 0.05, ΔΔp < 0.01 and ΔΔΔp < 0.001 
compared with lean control mice. 
 
Fig. 6. Effects of sea lamprey PYY(1-36) and (D-Arg35)-sea lamprey PYY(1-36) on β- and α-
cell survival in STZ-induced diabetic mice. All parameters were measured at after 14 days 
treatment with twice-daily injection of sea lamprey PYY(1-36) or (D-Arg35)-sea lamprey 
PYY(1-36) (both at 25 nmol/kg bw). Beta- and alpha-cell proliferation (A,B) and apoptosis 
(C,D) were assessed by Ki-67 and TUNEL immunoreactive staining, respectively. (E-H) 
Representative images of insulin and glucagon positive cells, co-stained with Ki-67 or TUNEL, 
for each treatment group are provided. Values are expressed as a fold-change of the lean control 
and are mean ± SEM for 10 mice, with 100-150 islets being analysed per group. *p < 0.05, **p 
< 0.01, ***p < 0.001 compared with STZ diabetic control mice. Δp < 0.05, ΔΔp < 0.01 and ΔΔΔp 
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